Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
WRAL Weather Alert Day issued for Sunday due to Level 2 risk for severe storms
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Summit Therapeu ADR
(NQ:
SMMT
)
11.60
-0.27 (-2.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeu ADR
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 20, 2023
Via
Benzinga
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
June 04, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Ivonescimab Updated Data to be Featured at ASCO 2023
June 01, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Why Shares of Summit Therapeutics Slumped on Tuesday
May 16, 2023
The company's shares have been falling since it announced earnings late last week.
Via
The Motley Fool
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 16, 2023
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.
Via
Benzinga
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
May 11, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
May 09, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Why Shares of Summit Therapeutics Soared This Week
May 05, 2023
Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer.
Via
The Motley Fool
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
May 03, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
March 21, 2023
From
Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
March 20, 2023
From
The Schall Law Firm
Via
Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
March 09, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Over $395M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying
March 09, 2023
The Dow Jones closed lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks...
Via
Benzinga
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
March 03, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Macy's, Big Lots, Sprouts Farmers Market And Other Big Stocks Moving Higher On Thursday
March 02, 2023
U.S. stocks traded mixed, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Workday, AdaptHealth And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 28, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. AdaptHealth Corp (NASDAQ: AHCO) shares dipped 18.3% to $17.95 in...
Via
Benzinga
Summit Therapeutics’ Rights Offering Nearing Expiration Date
February 23, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Acurx is Setting a High Bar for New Treatments in C. diff
February 14, 2023
A New Gold Standard for C. diff Therapy Could be in the Offing; Next Data Release Expected in 2Q23
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 03, 2023
Via
Benzinga
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday
February 03, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 03, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
February 03, 2023
Good morning! It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Why Alphabet And Amazon Are Trading Lower; Here Are 20 Stocks Moving Premarket
February 03, 2023
Gainers Nordstrom Inc. (NYSE: JWN) shares surged 29.56% to $27.39 in pre-market trading after activist investor Ryan Cohen took a stake in the company and announced he is planning to urge a board...
Via
Benzinga
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
January 30, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
Via
Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
January 27, 2023
Via
Benzinga
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
January 20, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
How Is The Market Feeling About Summit Therapeutics?
January 13, 2023
Summit Therapeutics's (NASDAQ:SMMT) short percent of float has fallen 21.45% since its last report. The company recently reported that it has 3.96 million shares sold short, which is 14.06% of all...
Via
Benzinga
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 10, 2023
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.